to obtain the best results in terms of survival. 4 Recent advances in therapeutic approaches for gastroesophageal tumours have significantly improved the curative resection rates, and both the diseasefree and the overall survival. [5] [6] [7] Nevertheless, no biomarkers are yet available to reliably predict tumor chemosensitivity. Recent findings indicate that squamous cell carcinoma antigen-1 (SCCA1) is upregulated during Barrett's carcinogenesis and predicts EAC resistance to neoadjuvant chemotherapy. 8 Squamous cell carcinoma antigen-1 is a serine protease inhibitor that belongs to the clade B subset of serpins and includes the 2 isoforms SCCA1-1 (also known as SerpinB3) and SCCA1-2 (also known as SerpinB4). [9] [10] [11] The first described isoform, SCCA1-1, was initially found to be significantly overexpressed in carcinomas with squamous differentiation, but recent evidence also extends to adenocarcinoma of the lung, breast, and pancreas, as well as hepatocellular carcinoma. [12] [13] [14] The SCCA1-1 isoform confers to cancer cells resistance to induced apoptosis by different mechanisms, including inhibition of lysosomal cathepsin proteases, the JNK pathway, or p38 activation. 9 More recently, the role of SCCA1-1 has been reported in inhibiting reactive oxygen species generation and cell death through its inhibitory interaction with respiratory complex I. 15 In addition, these and other studies have highlighted a significant association between SCCA1-1 overexpression and poor prognosis, also associated with chemoresistance in different tumor types. 9, [14] [15] [16] [17] Cancer immune surveillance mechanisms might significantly influence the prognosis of EAC, as it does in the case of colorectal cancer. 18 Several studies have indicated that in colorectal cancer the impairment of immune surveillance mechanisms plays a crucial role in cancer recurrence. 19, 20 Moreover, peritumoral adipose tissue plays a role in lymph node involvement in EAC. 21 Adipose tissue-derived mesenchymal stem cells can differentiate into cancer-associated fibroblasts under the influence of specific tumor-derived factors 22 and cumulative evidence supports the hypothesis that cancer-associated adipose tissue represents a key component in carcinogenesis. 23 On this basis, several studies investigated the relationship between the expression of specific stemness genes in tumor cells and their potential association to chemotherapy resistance.
In EAC, SCCA1 expression has never been investigated in relation to immune surveillance profile and to the peritumoral adipose tissue microenvironment. Therefore, the aim of our study was to investigate the potential mechanisms of SCCA1 expression leading to poor prognosis and chemoresistance in early and locally advanced EAC.
| MATERIAL S AND ME THODS

| Study design
Cancer tissue, peritumoral adipose tissue, and blood samples were 
| Preoperative staging and neoadjuvant therapy protocols
Preoperative staging and neoadjuvant therapy protocols are described in Document S1. 4 
| Surgical resection procedures and tissue sample collection
Details concerning surgical techniques have been published elsewhere. 24 Briefly, esophagectomy was carried out using an Ivor Lewis procedure, by laparotomy or laparoscopy, and right thoracotomy for tumors of the mid-lower esophagus and the gastric cardia. 25 During surgical procedures, biopsies of periesophageal adipose tissue and of tumoral and nontumoral mucosa were collected for each patient.
Fresh specimens were immediately frozen in liquid nitrogen, or fixed in formalin for subsequent analysis.
| Serological assays
| Free SCCA1 determination
The concentration of SCCA1 in serum was quantified by sandwich ELISA (Hepalisa kit) purchased from Xeptagen (Venice, Italy) following the manufacturer's instructions. Briefly, serum samples (100 μL) were incubated for 1 hour at room temperature on plates coated with rabbit anti-human-SCCA1 capture Ab (10 μg/mL in PBS, pH 7.4). This Ab recognizes both SCCA1 and SCCA12 isoforms.
Standard curve, obtained by dilution of recombinant SCCA1 from 20 to 0.25 ng/mL, was also included. All samples were tested in duplicate. After washing, SCCA1 was revealed by incubation with 100 μL HRP-conjugated streptavidin secondary anti-SCCA1 Ab (0.5 μg/mL).
The plate was developed with a ready-to-use 3,3', 5,5'-tetramethylbenzidine (TMB) substrate solution. The reaction was stopped with 1 mol/L HCl (100 μL) and absorbance at 450 nm was measured on a microplate reader (Victor × 3; Perkin Elmer, Waltham, MA, USA).
| Determination of SCCA1-IgM
Levels of SCCA1-IgM immune complexes were measured by HEPA-IC kit (Xeptagen), according to the manufacturer's instructions. Briefly, plates precoated with anti-human SCCA1 Ab were incubated with either serially diluted standards or serum samples in duplicate, and the presence of SCCA1-IgM complex was revealed by the addition of enzyme-conjugated anti-human IgM. The plates were then washed, and the substrate solution was incubated for 10-15 minutes. Subsequently, the plates were read on a microtiter plate reader at 450 nm. The amount of immune complex was expressed in Arbitrary Units/mL (AU/mL). The cut-off value of 156 AU/mL was calculated as the 95th percentile on the distribution curve of the assay in healthy subjects. 26 Forty-four healthy volunteers, used as controls, had their free SCCA1 and SCCA1-IgM serum levels quantified and compared to the corresponding EAC patients' serum levels.
| Flow cytometry analysis of esophageal mucosa
Tumor and corresponding normal mucosa tissue samples were mechanically dissected and passed through a sterile nylon filter (BD Falcon, Heidelberg, Germany). The single cell suspension was pelleted, suspended in FACS buffer (PBS/2% FCS/0.02% sodium azide) and stained with fluorochrome-conjugated Abs (Table S1) Dichotomous data are expressed as n (%) and continuous data as median (interquartile range). No statistically significant difference was observed between the 2 groups.
| Immunohistochemistry
TA B L E 1 Epidemiological and clinical characteristics of the patients included in the study, grouped according to level of squamous cell carcinoma antigen-1 (SCCA1)
within the peritumoral adipose tissue were also evaluated by IHC.
The primary Abs, murine IgG1, specific for the CD80, CD4, CD8, programmed death ligand-1 (PD-L1), PD-L2, and CD107 (Table S1) were added and incubated for 30 minutes at room temperature.
After several washes, the secondary Ab (horse Ig conjugated 
| Effect of SCCA1 on immune checkpoint gene expression
Recombinant LPS-free SCCA1 was obtained in our laboratory as previously described 27 and used at 200 ng/mL on isolated human primary monocytes (peripheral mononuclear cells [PMCs] ). Unless otherwise indicated, all other agents were of analytical grade and were purchased from Sigma (Saint Louis, MI, USA).
| Isolation and culture of human PMCs
Peripheral mononuclear cells from healthy donors were isolated by centrifugation on Ficoll-Paque solution at 500 rcf for 30 minutes. 
| Flow cytometry
Primary PMCs, stimulated or not with recombinant SCCA1
(200 nmol/L), were harvested and stained with fluorochromeconjugated Abs (Table S1) 
| External validation series
The validation series consisted of gene expression data from 75
samples from the University of Texas accessed from the Gene Expression Omnibus (GEO) databank (dataset ID: GSE13898). USA). In the cytotoxicity analysis, differences between groups were tested by applying the (unpaired) t test, using GraphPad Prism version 6.01 for Windows (GraphPad Software, San Diego, CA, USA). P values < .05 were considered significant for all the above-mentioned analysis.
| Statistics
| RE SULTS
| Levels of SCCA1 and patients' survival after EAC surgery
The extent of expression of SCCA1 within the tumor at transcription level is shown in Figure 1A . Figure 1B None of these parameters were correlated with disease-free survival ( Figure 1F ).
| Clinical parameters, SCCA1, and neoadjuvant therapy
As SCCA1 levels were inversely associated with patients' survival, we tested the possible associations between SCCA1 and age, neoadjuvant therapy, tumor stage, and N stage (Table S3) . Age was negatively associated with SCCA1-IgM (ρ = −0.29, P = .05) and positively associated with free SCCA1 (ρ = 0.28, P = 0.06) levels (Figure 2A) .
Patients who had previously received neoadjuvant therapy had lower serum SCCA1 levels (P = .01) and slightly higher tumor SCCA1 levels (P = .07) ( Figure 2B ). Among the patients receiving neoadjuvant therapy, the most frequent components of the chemotherapy scheme were 5-FU (33 patients), cisplatin (30 patients), docetaxel (12 patients), and oxaliplatin (6 patients). Tumor SCCA1 was higher in patients receiving docetaxel (P = .003) ( Figure 3A) , whereas SCCA1-IgM and free SCCA1 levels in serum were not significantly different in patients receiving docetaxel (Table S3) . 
| Squamous cell carcinoma antigen-1 and immune microenvironment within the tumor
To verify the hypothesis of a direct role of SCCA1 in EAC patients' (Table S4 ).
Tumor SCCA1 mRNA expression was inversely correlated to the MFI of CD80 expression on epithelial cells (ρ = −0.68, P = .03) ( Figure 4A ). Both SCCA1-IgM and free SCCA1 levels in serum were inversely correlated with immune activation markers. In particular, SCCA1-IgM serum levels were inversely correlated with CD80, CD86, and CD38 mRNA levels within the tumor ( Figure 4B ). In addition, SCCA1-IgM was significantly higher in patients with low peritumoral intraepithelial expression of CD107 ( Figure 4C,D) . Free SCCA1 serum levels were inversely correlated to TLR4 and CD38 mRNA levels within the tumor ( Figure 4C ) and they were significantly higher in patients with a low intraepithelial CD8 + lymphocyte rate ( Figure 4C,D) .
| Squamous cell carcinoma antigen-1 enhances the immune checkpoint genes expression
To verify the hypothesis of a possible direct role of SCCA1 in the de- Figure 5C . Moreover, data from 2 cell lines, OE19 and OE33 expressing low and high SCCA1 levels, respectively, showed that the last ones significantly expressed more PD-L1
( Figure 5D ). Finally, in the external validation cohort GSE13898, a significant direct correlation was observed between SCCA1 and PD-L1 mRNA levels within the tumor tissue ( Figure 5E ).
| Squamous cell carcinoma antigen-1 and peritumoral microenvironment
To investigate the association between SCCA1 and peritumoral microenvironment, we evaluated mRNA expression of stem cell markers (CD90, CD34, OCT-4, and NSTM) and paracrine adipose tissue mediators (adiponectin and leptin) in peritumoral adipose tissue.
Moreover, angiogenesis and lymphangiogenesis markers (CD31 and podoplanin) within the peritumoral adipose tissue were also evaluated by IHC. In peritumoral adipose tissue, SCCA1 was detectable in only 9 (20.9%) of the patients. It is interesting to note that the extent of SCCA1 expression within the tumor was directly associated with the levels of leptin in peritumoral adipose tissue ( Figure 6A ). In contrast, SCCA1 mRNA expression within the tumor was inversely correlated with CD34 mRNA levels both within the tumor and in the peritumoral adipose tissue ( Figure 6B ). The other variables analyzed were not associated with SCCA1 expression in any site (Table S5 ).
| D ISCUSS I ON
Recent findings indicate that SCCA1 is upregulated during Barrett's carcinogenesis and predicts EAC resistance to neoadjuvant chemotherapy. 8 In fact, several studies have highlighted a significant association between SCCA1 overexpression and poor cancer prognosis, also associated with chemoresistance in different tumor types. 9,15-17 Squamous cell carcinoma antigen-1 confers to cancer cells resistance inhibiting apoptosis and reactive oxygen species generation and cell death. 9, 15 Moreover, cancer immune surveillance mechanisms might significantly influence the prognosis of EAC and in this cancer setting SCCA1 expression has never been investigated in relation to immune surveillance profile and to the peritumoral adipose tissue microenvironment.
In our series of EAC patients, free SCCA1 serum levels were significantly higher and SCCA1-IgM serum levels were significantly lower than in healthy controls. Moreover, in EAC patients, SCCA1
high serum levels of free SCCA1 were associated with significantly worse overall survival, and SCCA1-IgM serum levels showed a trend to a worse overall survival. These findings might reflect a decline of the natural immune surveillance, as IgM bound to SCCA1 is likely an expression of immune control, in line with the recent theory of cancer immunoediting. 30 The impairment of immunosurveillance, which can physiologically slightly increase with age, 31 might All graphs depict mean ± SEM. E, An independent study in the NCBI GEO database showed a significant correlation between SCCA1 and PD-L1 mRNA levels in esophageal adenocarcinoma tissues explain the higher levels of free SCCA1 detected in serum of the patients with worse survival. In line with our results, positivity for SCCA1 identified a subgroup of patients with non-small-cell lung carcinoma who had poor survival after chemotherapy.
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In our series, patients who had previously received neoadjuvant therapy had slightly higher tumor SCCA1 levels; this finding might somehow reflect the selection criteria for the patients undergoing anticancer treatment, as this approach was reserved for patients with more aggressive features (i.e. nodal metastasis). In a previous study, we had observed that SCCA1 overexpression was associated with chemoresistance in patients with EAC. 8 Furthermore, SCCA1 overexpression has also been associated with chemoresistance in several different other tumor types. 16, 17 Moreover, as we observed that tumor SCCA1 mRNA expression was higher in patients receiving docetaxel, we focused on the possible modulation of cell viability by SCCA1 in the presence of different chemotherapeutic drugs. We observed that OE33 cells, overexpressing SCCA1, were more resistant to cell death than the control OE19 cells after treatment with epirubicin, docetaxel, and cisplatin, whereas cell viability was not af- This result is consistent with the higher SCCA1 mRNA expression in those who had received docetaxel because in these patients the cells surviving this type of chemotherapy are probably expressing SCCA1.
Moreover, our research group has observed that SCCA1 shields cells from the toxicity of drugs with a pro-oxidant action, such as doxorubicin and cisplatin. 15 It is worth noting that these drugs are among the most commonly used in neoadjuvant therapy for EAC. Thus, a reduced chemosensitivity in patients with high levels of SCCA1 could explain, at least in part, the poor prognosis of these patients.
To complete the possible cause of worse survival in patients with high SCCA1 levels, we verified the hypothesis of possible cross-talk between SCCA1 and the tumor immune microenvironment. In fact, we observed that tumor SCCA1 mRNA expression was inversely correlated to the MFI of CD80 expression on epithelial cells. CD80
is a co-stimulatory molecule necessary to the proper activation of T cells during antigen presentation. 33 Its expression on epithelial cells was reported to be the main driver of immune surveillance mechanisms in inflammatory colorectal carcinogenesis. 18 Ipilimumab, an anti-CTLA-4 Ab (CTLA-4 is the physiological inhibitor of CD80 and CD86) was indeed declared molecule of the year in 2013 at the beginning of the immunotherapy revolution. 34 The inverse correlation of SCCA1 with CD80 expression on the epithelial cell surface might suggest an important clue on the immune inhibitory role of SCCA1.
In fact, total bulk of SCCA1, including IgM-bound and free forms, was inversely correlated with immune activation markers such as CD80, CD86, TLR4, and CD38 mRNA levels within the tumor and as peritumoral intraepithelial expression of CD8 + and CD107 + cells. All these data indicate the presence of a direct or an indirect effect of high levels of SCCA1 expression on the immune surveillance mechanisms, resulting in intratumoral immunity impairment that might concur with the worse prognosis of patients with high SCCA1 expression.
To verify the hypothesis of a possible direct role of SCCA1 in the depression of the tumor immune response, human recombinant SCCA1 was added to different immune cell subsets. In the CD14 + monocyte cell subset a significant increase of PD-L1, but not PD-L2, was observed and these findings were confirmed by IHC in tumor specimens.
Moreover, PD-L1 levels were higher in OE33 cells, expressing SCCA1, than in OE19 cells, not expressing SCCA1. It is worth noting that in the external validation cohort GSE13898, 28 a significant direct correlation between SCCA1 and PD-L1 mRNA levels within the tumor tissue was also detected. Taken together, all these data provide different and consistent in vivo and in vitro proof that these 2 molecules are expressed at the same time in EAC, although the precise pathogenetic mechanism of their association still remains to be elucidated.
In addition, these results agree with the recent report of a direct association between SCCA1 and the expression of immune checkpoint regulators PD-L1/PD-L2 in head and neck squamous cell carcinoma. 35 Interestingly, in a very recent multicohort, phase IB study, pembrolizumab, an anti-PD-L1 Ab, showed manageable toxicity and durable antitumor activity in patients with heavily pretreated, PD-L1-positive advanced esophageal carcinoma. 36 The increased levels of PD-L1 expression in EAC, induced by SCCA1, might contribute to the observed F I G U R E 6 Squamous cell carcinoma antigen-1 (SCCA1) and peritumoral microenvironment parameters in patients with esophageal adenocarcinoma. A, Spearman rank correlation analysis of tumor SCCA1 mRNA and peritumoral Leptin mRNA levels. B, Spearman rank correlation analysis of tumor SCCA1 mRNA and peritumoral CD34 mRNA levels intratumoral immune impairment. These findings suggest that SCCA1 might be used as a predictive marker of response to immunotherapy and might support the use of different strategies to enhance the response to immunotherapy in future studies.
Finally, to investigate the association between SCCA1 and the peritumoral microenvironment, we evaluated SCCA1 expression, stem cell markers, and paracrine adipose tissue mediators in peritumoral adipose tissue that had been proven to play a significant role in the nodal metastatic process and in chemoresistance. 21, 36 In our series, SCCA1 expression within the tumor was inversely correlated with CD34 levels, both within the tumor and in the peritumoral adipose tissue. It is likely that hypoxia, more evident in tumors with low angiogenesis and therefore low levels of the endothelial marker CD34, can contribute to SCCA1 induction through a hypoxia-inducible factor-2α mediated mechanism. 37 Moreover, we observed that the extent of SCCA1 expression within the tumor was directly correlated with the levels of leptin in peritumoral adipose tissue. As we failed to determine a direct effect of SCCA1 in leptin secretion in vitro (data not shown), this direct correlation might be due to the independent activity or dependence of other factor(s) of both molecules, leading to poor response to chemotherapy and poor prognosis. 21 In conclusion, SCCA1 is associated with poor prognosis in esophageal cancer patients. This finding might be due to the following identified mechanisms induced, at least in part, by SCCA1: 
CO N FLI C T S O F I NTE R E S T
The authors have no conflicts of interest.
O RCI D
Elisabetta Trevellin
https://orcid.org/0000-0002-5647-362X
Marco Scarpa
https://orcid.org/0000-0002-0217-6523
